Delivery Order SPE2DB20D1047-SPE2DB25FF79C
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.42 on August 19, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL). This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procurement with no set-aside designation. The place of...
- The Defense Logistics Agency awarded a $4,196.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10mL) on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The U.S. Department of Defense's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $1,463.20 for Insulin Aspart 100 Unit/mL vials (10mL) on July 18, 2025, with an ultimate completion date of July 21, 2025. This firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL) with a ceiling value of $2,262.05. This is a firm fixed-price delivery order with an ultimate completion date of July 24, 2025, and represents a non-competitive set-aside contract. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate...
- The Defense Logistics Agency awarded a $5,030.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL). The contract is non-set-aside and competitively awarded, with performance scheduled for completion by August 13, 2025, at the awardee's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,585.72 for the supply of Insulin Aspart 100 Unit/mL vials (10mL) under a firm fixed price contract. This non-set-aside award was issued on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract worth $10,637.56 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 4,564,298,990 units of Insulin Aspart 100 Unit/mL pen 3mL. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. The IDC allows the DLA to efficiently procure a...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Insulin Aspart 100 Unit/mL in 10 mL vials. The contract has a ceiling value of $1,097.40 and an ultimate completion date of May 30, 2025. This order is not designated as a set-aside contract. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,491.83 firm fixed-price delivery order is for the supply of Insulin Aspart 100 Unit/mL Pen, 3mL, a diabetes medication. The contract has an ultimate completion date of April 18, 2025 and is not set aside for any special type of business. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The contract, valued at $2,822.60, is for the delivery of Insulin Aspart 100 Unit/ML Vials 10ML to support military treatment programs and facilities. This delivery order is part of a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, with a...
- SPE2DB20D1047Indefinite Delivery Contract
- SPE2DB20D1047-SPE2DB25FF79CDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL) under a firm fixed-price contract with a ceiling value of $1,238.72. The contract, which is not set-aside and competitively awarded, is scheduled for completion by August 22, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal vendor for military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply a wide range of pharmaceutical products, medical devices, and healthcare commodities across multiple therapeutic domains. This insulin supply contract supports the Defense Health Agency's pharmaceutical procurement needs, leveraging AmerisourceBergen's established position as a prime vendor within DLA's medical supply chain infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 8/21/25 |